On August 12, Core Scientific, Inc. rose 9.11% in regular trading, trading at $21.18/share, with turnover of $31.93 million.

The rebound was driven by a confluence of factors: the stock had previously declined sharply following a disappointing Q2 earnings report, creating strong technical rebound demand. Sector-wide recovery provided further tailwinds, with peer stocks IREN rising 8.3% and Riot Platforms gaining 3.11% on the same day. Additionally, B. Riley raised its price target to $42 from $33 while maintaining a Buy rating, and Keefe Bruyette upgraded the stock to Outperform with a $28 target, providing valuation support.

However, headwinds persist. The company reported a Q2 net loss of $3.32 per share, far exceeding the consensus estimate of a $0.06 loss, despite revenue of $164.2 million beating expectations. Concerns over share dilution from warrants granted to AMD under a data center partnership of up to 2.5 gigawatts also continue to weigh on sentiment, leaving the sustainability of the rebound uncertain.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)